药品审批
药物开发
医学
药品
小儿肿瘤学
抗癌药
肿瘤科
药理学
重症监护医学
癌症
内科学
作者
Joshua Donaldson,Marjilla Seddiq,Michael Fusco,Shyamli Singla,Gulsum E. Pamuk,Rosa J. Lee-Alonzo,Bronwyn D. Mixter,Kirsten B. Goldberg,Laleh Amiri‐Kordestani,R. Angelo de Claro,Nicole Drezner,Nicole J. Gormley,Bindu Kanapuru,Steven J. Lemery,Lola A. Fashoyin-Aje,Nicholas C. Richardson,Harpreet Singh,Daniel L. Suzman,Marc R. Theoret,Paul G. Kluetz,Richard Pazdur
出处
期刊：Cancer Discovery
[American Association for Cancer Research]
日期：2023-12-12
卷期号：13 (12): 2515-2524
被引量：1
标识
DOI：10.1158/2159-8290.cd-23-1226
摘要
Summary: Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI
cctv18
ppg123
一一
彭于彦祖
monere
maox1aoxin
zho
港岛妹妹
嗯哼
小鱼爱吃肉
背带裤打篮球
tuanheqi
坚强的广山
pluto
8R60d8
36456657
besatified
不配.
带头大哥
双黄
皖公网安备34019202002308
